Browse News
Filter News
Found 412 articles
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - September 8, 2023
9/8/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on September 06, 2023, the compensation committee of BridgeBio’s board of directors granted twenty-four new employees restricted stock units for an aggregate of 154,186 shares of the Company’s common stock.
-
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
9/7/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Tuesday, September 12 at 10:50 am ET.
-
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
9/6/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced positive feedback from the U.S. FDA and the EU EMA on key elements of the trial design for PROPEL3, its pivotal Phase 3 study of infigratinib in children with achondroplasia.
-
The late-stage results for acoramidis, BridgeBio’s transthyretin amyloid cardiomyopathy candidate, indicate significant survival, functional and biomarker improvements over placebo.
-
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
8/27/2023
BridgeBio Pharma, Inc. announced the presentation of detailed positive results from its Phase 3 ATTRibute-CM study of acoramidis for patients with ATTR-CM by Julian Gillmore, MBBS, M.D., Ph.D., FRCP, FRCPath, in a Hot Line session at the European Society of Cardiology Congress 2023.
-
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
8/24/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”) announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2023, taking place in Amsterdam, Netherlands on August 25 - 28, 2023.
-
Biotech startups often struggle with hiring decisions. Incubators can help through mentorship opportunities and by bringing in potential talent.
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - August 4, 2023
8/4/2023
BridgeBio Pharma, Inc. today announced that on August 02, 2023, the compensation committee of BridgeBio’s board of directors granted seven new employees restricted stock units for an aggregate of 26,657 shares of the Company’s common stock.
-
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
8/3/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the second quarter ended June 30, 2023 and provided an update on the Company’s operations.
-
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
8/3/2023
LianBio (Nasdaq: LIAN) today announced the first patient has been dosed in its Phase 1 clinical trial of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mutations.
-
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
7/31/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”) today announced that, based on discussions with the U.S. Food and Drug Administration (FDA), there is a potential path to pursue accelerated approval in the U.S. for BBP-418, an investigational oral substrate supplementation therapy, in patients with limb-girdle muscular dystrophy type 2I (LGMD2I/R9).
-
The program—a joint initiative between CDER and CBER—aims to accelerate the development of therapies for rare diseases.
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 18, 2023
7/18/2023
BridgeBio Pharma, Inc. today announced that on July 10, 2023, the compensation committee of BridgeBio’s board of directors granted eight new employees restricted stock units for an aggregate of 71,250 shares of the Company’s common stock.
-
Following disappointing topline data, BridgeBio’s acoramidis has scored a late-stage win in transthyretin amyloid cardiomyopathy, leading to significant survival and quality of life benefits.
-
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
7/17/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.
-
BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
7/14/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) today announced that members of its management team will host an investor call on Monday, July 17 at 8:00 am ET to share topline results from the Phase 3 ATTRibute-CM clinical study in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
-
Burjeel Holdings and BridgeBio Pharma ink partnership deal in rare genetic diseases with a plan to set up headquarters in Abu Dhabi.
-
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
7/12/2023
LianBio today announced a clinical supply agreement with AstraZeneca in China to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor.
-
Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma
7/12/2023
Burjeel Holdings and BridgeBio Pharma, Inc. have announced a new project to revolutionize the field of early diagnosis and treatment of rare diseases or disorders in the UAE and the region.
-
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
6/20/2023
BridgeBio Pharma, Inc. presented updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating a continued potentially best-in-class efficacy and safety profile at the Endocrine Society (ENDO) 2023 Annual Conference.